Physician profile

Lawrence S Stone

Ophthalmology · Chicago, IL

NPI 1396824942

$954.56

in general payments reported to CMS, 2019-2025

9 companies · none reported in 2025

See the full distribution for Ophthalmology

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Debt Forgiveness$548.74
Food and Beverage$22.37

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Quidel Corporation $548.74 2023
Allergan, INC. $152.11 2020-2021
Sun Pharmaceutical Industries INC. $109.85 2022
Aerie Pharmaceuticals, INC. $54.07 2019
Abbvie INC. $22.37 2023 Durysta
Carl Zeiss Meditec Ag $19.40 2020
Tearlab Corp $18.52 2021
Novartis Pharmaceuticals Corporation $18.50 2021
Biotissue Holdings INC. $11.00 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Lawrence S Stone

$954.56

in general payments reported 2019-2025

Years
2019-2023
Top company
Quidel Corporation

https://glasscript.com/doctor/153702/lawrence-s-stone

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.